September 2024 SCRI Release Copied
SCRI Trials and Trial Regimen Updates
The following updates were completed between Aug. 23, 2024, through Sept. 20, 2024. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 23337 | USOR 23337 MEL 74 Phase 2/3 Comparator Arm Dacarbazine Q21D
USOR 23337 MEL 74 Phase 2/3 Comparator Arm Ipilimumab + Nivolumab Q21D USOR 23337 MEL 74 Phase 2/3 Comparator Arm Maintenance Nivolumab Q28D USOR 23337 MEL 74 Phase 2/3 Comparator Arm Pembrolizumab Q21D USOR 23337 MEL 74 Phase 2/3 Treatment Arm IDE196 (Darovasertib) + Crizotinib Q21D |
23335 | USOR 23335 MEL 81 Phase 3 Arm A Fianlimab + Cemiplimab Q21D
USOR 23335 MEL 81 Phase 3 Arm B Nivolumab + Relatlimab (Opdualag) Q28D |
|
23306 |
USOR 23306 LUN 553 Phase 1B/2 Cohort 1 Part A Maintenance I-DXd + Atezolizumab Q21D
USOR 23306 LUN 553 Phase 1B/2 Cohort 1 Part B Induction Etoposide + Atezolizumab + Carboplatin Q21D USOR 23306 LUN 553 Phase 1B/2 Cohort 1 Part B Maintenance Arm 1 I-DXd + Atezolizumab Q21D USOR 23306 LUN 553 Phase 1B/2 Cohort 1 Part B Maintenance Arm 2 I-DXd + Atezolizumab Q21D USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part A Induction I-DXd + Atezolizumab + Carboplatin Q21D USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part A Maintenance I-DXd + Atezolizumab Q21D USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part B Induction Arm 3 I-DXd + Atezolizumab + Carboplatin Q21D USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part B Induction Arm 4 I-DXd + Atezolizumab + Carboplatin Q21D USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part B Maintenance Arm 3 I-DXd + Atezolizumab Q21D USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part B Maintenance Arm 4 I-DXd + Atezolizumab Q21D |
|
23333 |
USOR 23333 MPN 20 Phase 3 Randomized Navtemadlin or Placebo D1-7 + Ruxolitinib Q28D
USOR 23333 MPN 20 Phase 3 Run-in Monotherapy Ruxolitinib Q28D |
|
22273 |
USOR 22273 LYM 238 Phase 3 Arm A Zanubrutinib + Obinutuzumab D1,8,15 fb D1 Q28D
USOR 22273 LYM 238 Phase 3 Arm B Rituximab D1,8,15,22 fb D1 + Lenalidomide Q28D USOR 22273 LYM 238 Phase 3 Arm C Zanubrutinib + Rituximab D1,8,15,22 fb D1 Q28D USOR 22273 LYM 238 Phase 3 Arm D Rituximab D1,8,15,22 fb D1 + Lenalidomide Q28D |
|
24004 |
USOR 24004 HN 33 Phase 3 Cetuximab D1,8,15,22 Q28D
USOR 24004 HN 33 Phase 3 Docetaxel D1,8,15,22 Q28D USOR 24004 HN 33 Phase 3 Methotrexate D1,8,15,22 Q28D USOR 24004 HN 33 Phase 3 Petosemtamab D1,15 Q28D |
|
23234 |
USOR 23234 Arm A Volrustomig Q21D |
|
24026 |
USOR 24026 BRE 440 Phase 1b/2 Dose Escalation RYZ101 Q42D |
|
24063 |
USOR 24063 GU 241 Phase 2 Cohort A Vudalimab (XmAb20717) + Carboplatin + Cabazitaxel Q28D
USOR 24063 GU 241 Phase 2 Cohort E Vudalimab (XmAb20717) + Docetaxel Q28D |
|
23304 |
USOR 23304 Multi 84 Phase I Part 1 Dose Escalation TORL-1-23 Q21D |
|
23170 |
USOR 23170 | LUN 543 | Phase 3 | Pembrolizumab + Pemetrexed + Carboplatin Q21D
USOR 23170 | LUN 543 | Phase 3 | Pembrolizumab + Pemetrexed + Cisplatin Q21D USOR 23170 | LUN 543 | Phase 3 | Zongertinib (PO; Daily) Q21D USOR 23170 | LUN 543 | Phase 3 | BI 1810631 Q21D USOR 23170 | LUN 543 | Phase 3 | Pemetrexed Premedications |
Updated Reference Information
| Study Number | Updated Reference Information |
| 22325 | PA3, 04Jun2024 |
| 22106 | PA V3.0 |
| 23288 | Dose escalation memo
1.8 to 2.7mg, 14Jun2024 |
| 22003 | PAv10.0, 05Jun2024 |
| 22322 | PA vD, 02/09/2024 PA vE, 04/12/2024 |
| 22106 | PA v3.0 |
| 21270 | DIL: Azenosertib 21Jun2024 |
| 19062 | PA4.0 Pharmacy Manual v6 |
| 23292 | V16.1 |
| 23212 | PA v3.0, 28 May 2024 |
| 23048 | csp-v4 |
| 21365 | V4 18JUN24 |
| 23120 | V7.2 20JUN2024 |
| 22298 | V8 11JUN2024 |
| 23170 | V3.0 |
| 22133 | v3.0_26Jun2024 |
| 23292 | PA V17 |
| 22093 | PA 9 13Aug2024 |